Trial Profile
Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jun 2021
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary) ; Carboplatin
- Indications Advanced breast cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms CEP-1
- Sponsors Noxopharm
- 30 May 2021 Status changed from active, no longer recruiting to completed.
- 10 Apr 2019 According to a Noxopharm media release, this study enrolled 19 patients with late-stage metastatic, solid cancers (breast, lung, ovarian, prostate).
- 29 Nov 2018 According to a Noxopharm media release, data from phase 1b portion of the this study were presented at the Clinical Oncology Society of Australia (COSA) Annual Meeting (Nov 2018).